These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
521 related articles for article (PubMed ID: 26386787)
61. A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions. Jabbour RJ; Ielasi A; Tanaka A; Leoncini M; Cortese B; Grigis G; Mitomo S; Regazzoli D; Di Palma G; Rapetto C; Tespili M; Colombo A; Latib A Cardiovasc Revasc Med; 2017; 18(5S1):S4-S9. PubMed ID: 28314675 [TBL] [Abstract][Full Text] [Related]
62. Bioresorbable Vascular Scaffolds Versus Drug-Eluting Stents for Diffuse Long Coronary Narrowings. Seo J; Ahn JM; Hong SJ; Kang DY; Hong SJ; Her AY; Kim YH; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Park SJ; Park DW; Hong MK Am J Cardiol; 2020 Jun; 125(11):1624-1630. PubMed ID: 32279841 [TBL] [Abstract][Full Text] [Related]
63. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial. Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662 [TBL] [Abstract][Full Text] [Related]
64. Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial. Zhang YJ; Bourantas CV; Muramatsu T; Iqbal J; Farooq V; Diletti R; Campos CA; Onuma Y; Garcia-Garcia HM; Serruys PW EuroIntervention; 2014 Oct; 10(6):672-80. PubMed ID: 24472767 [TBL] [Abstract][Full Text] [Related]
66. One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials. de Ribamar Costa J; Abizaid A; Bartorelli AL; Whitbourn R; Jepson N; Perin M; Steinwender C; Stuteville M; Ediebah D; Sudhir K; Serruys PW EuroIntervention; 2016 Nov; 12(10):1255-1262. PubMed ID: 27866134 [TBL] [Abstract][Full Text] [Related]
67. Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males: Results of an Individual Patient-Level Pooled Meta-Analysis of Randomized Controlled Trials. Shreenivas S; Kereiakes DJ; Ellis SG; Gao R; Kimura T; Onuma Y; Piard-Ruster K; Zhang Y; Koo K; Vu MT; Serruys PW; Stone GW JACC Cardiovasc Interv; 2017 Sep; 10(18):1881-1890. PubMed ID: 28935081 [TBL] [Abstract][Full Text] [Related]
68. Italian Diffuse/Multivessel Disease ABSORB Prospective Registry (IT-DISAPPEARS). Study design and rationale. Testa L; Biondi Zoccai G; Tomai F; Ribichini F; Indolfi C; Tamburino C; Bartorelli A; Petronio AS; Bedogni F; De Carlo M J Cardiovasc Med (Hagerstown); 2015 Mar; 16(3):253-8. PubMed ID: 25469734 [TBL] [Abstract][Full Text] [Related]
69. Everolimus-eluting Bioresorbable Vascular Scaffold Implantation in Real World and Complex Coronary Disease: Procedural and 30-day Outcomes at Two Australian Centres. Robaei D; Back LM; Ooi SY; Pitney MR; Jepson N Heart Lung Circ; 2015 Sep; 24(9):854-9. PubMed ID: 25778622 [TBL] [Abstract][Full Text] [Related]
70. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423 [TBL] [Abstract][Full Text] [Related]
71. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Brener SJ; Kereiakes DJ; Simonton CA; Rizvi A; Newman W; Mastali K; Wang JC; Caputo R; Smith RS; Ying SW; Cutlip DE; Stone GW Am Heart J; 2013 Dec; 166(6):1035-42. PubMed ID: 24268218 [TBL] [Abstract][Full Text] [Related]
72. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884 [TBL] [Abstract][Full Text] [Related]
73. Vasomotor Function Comparative Assessment at 1 and 2 Years Following Implantation of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold and the Xience V Everolimus-Eluting Metallic Stent in Porcine Coronary Arteries: Insights From In Vivo Angiography, Ex Vivo Assessment, and Gene Analysis at the Stented/Scaffolded Segments and the Proximal and Distal Edges. Gogas BD; Benham JJ; Hsu S; Sheehy A; Lefer DJ; Goodchild TT; Polhemus DJ; Bouchi YH; Hung OY; Yoo SY; Joshi U; Giddens DP; Veneziani A; Quyyumi A; Rapoza R; King SB; Samady H JACC Cardiovasc Interv; 2016 Apr; 9(7):728-41. PubMed ID: 27056313 [TBL] [Abstract][Full Text] [Related]
74. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment. Gil RJ; Bil J; Pawłowski T; Yuldashev N; Kołakowski L; Jańczak J; Jabłoński W; Paliński P Kardiol Pol; 2016; 74(7):627-33. PubMed ID: 26779846 [TBL] [Abstract][Full Text] [Related]
76. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. Mattesini A; Secco GG; Dall'Ara G; Ghione M; Rama-Merchan JC; Lupi A; Viceconte N; Lindsay AC; De Silva R; Foin N; Naganuma T; Valente S; Colombo A; Di Mario C JACC Cardiovasc Interv; 2014 Jul; 7(7):741-50. PubMed ID: 25060016 [TBL] [Abstract][Full Text] [Related]
77. Bioresorbable scaffolds compared with everolimus-eluting stents for the treatment of chronic coronary total occlusion: clinical and angiographic results of a matched paired comparison. Kugler C; Markovic S; Rottbauer W; Wöhrle J Coron Artery Dis; 2017 Mar; 28(2):120-125. PubMed ID: 27845998 [TBL] [Abstract][Full Text] [Related]
78. The Current Literature on Bioabsorbable Stents: a Review. Omar WA; Kumbhani DJ Curr Atheroscler Rep; 2019 Nov; 21(12):54. PubMed ID: 31768641 [TBL] [Abstract][Full Text] [Related]
79. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries. Lane JP; Perkins LE; Sheehy AJ; Pacheco EJ; Frie MP; Lambert BJ; Rapoza RJ; Virmani R JACC Cardiovasc Interv; 2014 Jun; 7(6):688-95. PubMed ID: 24835327 [TBL] [Abstract][Full Text] [Related]
80. Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. Park DW; Kim YH; Song HG; Ahn JM; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Seung KB; Yang TH; Lee SG; Lee JH; Seong IW; Cheong SS; Lee BK; Lee NH; Lee SW; Lee SW; Lee K; Kim HS; Jeon DS; Kim MK; Nah DY; Tahk SJ; Park SJ JACC Cardiovasc Interv; 2011 Oct; 4(10):1096-103. PubMed ID: 22017935 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]